Plasma vitamin C concentrations predict the risk of incident stroke over 10 years in 20,649 participants of the EPIC-Norfolk prospective population study

Department of Public Health and Primary Care, University of Cambridge, United Kingdom.
American Journal of Clinical Nutrition (Impact Factor: 6.77). 02/2008; 87(1):64-9.
Source: PubMed


The relation between plasma vitamin C and risk of stroke remains unclear. Although clinical trials showed no significant benefit of vitamin C supplementation in reducing stroke risk, they were not able to examine the relation between plasma vitamin C concentrations and stroke risk in a general population.
The objective was to examine the relation between baseline plasma vitamin C concentrations and risk of incident stroke in a British population.
A population-based prospective study was conducted in 20,649 men and women aged 40-79 y without prevalent stroke at baseline and participating in the European Prospective Investigation into Cancer-Norfolk prospective population study. The participants completed a health questionnaire and attended a clinic during 1993-1997 and were followed up for incident strokes through March 2005.
Over 196,713 total person-years (average follow-up: 9.5 y), 448 incident strokes occurred. In a Cox proportional hazards model, persons in the top quartiles of baseline plasma vitamin C concentrations had a 42% lower risk (relative risk: 0.58; 95% CI: 0.43, 0.78) than did those in the bottom quartile, independently of age, sex, smoking, body mass index, systolic blood pressure, cholesterol, physical activity, prevalent diabetes and myocardial infarction, social class, alcohol consumption, and any supplement use. Similar results were obtained after exclusion of persons with illnesses, users of ascorbic acid-containing supplements, and persons with a history of early strokes during the initial 2 y of follow-up.
Plasma vitamin C concentrations may serve as a biological marker of lifestyle or other factors associated with reduced stroke risk and may be useful in identifying those at high risk of stroke.

Download full-text


Available from: Phyo K Myint,
  • Source
    • "30% lower risk of death from stroke compared to subjects with lower vitamin C levels. Myint et al., 2008 20,649 men and women 78.1 µmol/L "
    [Show abstract] [Hide abstract]
    ABSTRACT: The recommended dietary allowance (RDA) of vitamin C has traditionally been based on the prevention of the vitamin C deficiency disease, scurvy. While higher intakes of vitamin C may exert additional health benefits, the limited Phase III randomized placebo-controlled trials (RCTs) of vitamin C supplementation have not found consistent benefit with respect to chronic disease prevention. To date, this has precluded upward adjustments of the current RDA. Here we argue that Phase III RCTs-designed principally to test the safety and efficacy of pharmaceutical drugs-are ill suited to assess the health benefits of essential nutrients; and the currently available scientific evidence is sufficient to determine the optimum intake of vitamin C in humans. This evidence establishes biological plausibility and mechanisms of action for vitamin C in the primary prevention of coronary heart disease, stroke, and cancer; and is buttressed by consistent data from prospective cohort studies based on blood analysis or dietary intake and well-designed Phase II RCTs. These RCTs show that vitamin C supplementation lowers hypertension, endothelial dysfunction, chronic inflammation, and Helicobacter pylori infection, which are independent risk factors of cardiovascular diseases and certain cancers. Furthermore, vitamin C acts as a biological antioxidant that can lower elevated levels of oxidative stress, which also may contribute to chronic disease prevention. Based on the combined evidence from human metabolic, pharmacokinetic, and observational studies and Phase II RCTs, we conclude that 200 mg per day is the optimum dietary intake of vitamin C for the majority of the adult population to maximize the vitamin's potential health benefits with the least risk of inadequacy or adverse health effects.
    Critical reviews in food science and nutrition 09/2012; 52(9):815-29. DOI:10.1080/10408398.2011.649149 · 5.18 Impact Factor
  • Source
    • "(prostate), HepG2 (liver), MCF7 (breast), and Ishikawa (cervix). They were incubated in the presence of various concentrations of ascorbate, from 50 μM, which corresponds to baseline plasma vitamin C concentrations observed in humans [27] [28], up to 33 mM (Fig. 2A). A 2-h exposure was used for all the in vitro experiments, to mimic a clinical iv use, and cellular viability was checked 48 h later using the MTT reduction assay. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently, it has been proposed that pharmacologic concentrations of ascorbate (vitamin C) can be reached by intravenous injection. Because high doses of ascorbate have been described to possess anticancer effects, the therapeutic potential of these concentrations has been studied, both in vitro and in vivo. By using 2-h exposures, a protocol that mimics a parenteral use, we observed that pharmacologic concentrations of ascorbate killed various cancer cell lines very efficiently (EC50 ranging from 3 to 7 mM). The mechanism of cytotoxicity is based on the production of extracellular hydrogen peroxide and involves intracellular transition metals. In agreement with what has been previously published, our in vivo results show that both intravenous and intraperitoneal administration of ascorbate induced pharmacologic concentrations (up to 20 mM) in blood. In contrast, the concentrations reached orally remained physiological. According to pharmacokinetic data, parenteral administration of ascorbate decreased the growth rate of a murine hepatoma, whereas oral administration of the same dosage did not. We also report that pharmacologic concentrations of ascorbate did not interfere with but rather reinforced the activity of five important chemotherapeutic drugs. Taken together, these results confirm that oral and parenteral administration of ascorbate are not comparable, the latter resulting in pharmacologic concentrations of ascorbate that exhibit interesting anticancer properties.
    Free Radical Biology and Medicine 07/2009; 47(1-47):32-40. DOI:10.1016/j.freeradbiomed.2009.02.016 · 5.74 Impact Factor
  • Source
    • "Serum vitamin C concentration was inversely associated with incidence of stroke, both cerebral infarction and haemorrhagic stroke Polidori et al. (2001) (171) Vitamins C and E, uric acid and ubiquinol-10 Forty control subjects, thirteen patients with intracranial haemorrhage, fifteen patients with head trauma Intracranial and head trauma patients had significantly lower plasma levels of vitamin C compared with healthy subjects. Ascorbic acid was significantly inversely correlated with the severity of the neurological impairment and with the major diameter of the lesion Kurl et al. (2002) (145) Vitamin C and risk of stroke 2419 men with no history of stroke at baseline examination aged 42– 60 years Low plasma vitamin C was associated with an increased risk of stroke, especially among hypertensive and overweight men Vokó et al. (2003) (172) Intake of antioxidants from food and risk of stroke 5197 participants High dietary intake of antioxidants, in particular vitamin C and – in smokers – vitamin E, reduced the risk of stroke Myint et al. (2008) (146) Plasma vitamin C concentrations and risk of incident stroke 20 649 men and women without prevalent stroke at baseline aged 40–79 years Plasma vitamin C concentrations may serve as a biological marker of lifestyle or other factors associated with reduced stroke risk and may be useful in identifying those at high risk of stroke Intervention studies Shorer et al. (1996) (123) Vitamin E deficiency Four siblings Vitamin E administration in pharmacological doses improved the neurological condition in two patients and also corrected some of the patients' erythrocyte cell abnormalities "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the present review concerning stroke, we evaluate the roles of B vitamins, homocysteine and antioxidant vitamins. Stroke is a leading cause of death in developed countries. However, current therapeutic strategies for stroke have been largely unsuccessful. Several studies have reported important benefits on reducing the risk of stroke and improving the post-stroke-associated functional declines in patients who ate foods rich in micronutrients, including B vitamins and antioxidant vitamins E and C. Folic acid, vitamin B6 and vitamin B12 are all cofactors in homocysteine metabolism. Growing interest has been paid to hyperhomocysteinaemia as a risk factor for CVD. Hyperhomocysteinaemia has been linked to inadequate intake of vitamins, particularly to B-group vitamins and therefore may be amenable to nutritional intervention. Hence, poor dietary intake of folate, vitamin B6 and vitamin B12 are associated with increased risk of stroke. Elevated consumption of fruits and vegetables appears to protect against stroke. Antioxidant nutrients have important roles in cell function and have been implicated in processes associated with ageing, including vascular, inflammatory and neurological damage. Plasma vitamin E and C concentrations may serve as a biological marker of lifestyle or other factors associated with reduced stroke risk and may be useful in identifying those at high risk of stroke. After reviewing the observational and intervention studies, there is an incomplete understanding of mechanisms and some conflicting findings; therefore the available evidence is insufficient to recommend the routine use of B vitamins, vitamin E and vitamin C for the prevention of stroke. A better understanding of mechanisms, along with well-designed controlled clinical trials will allow further progress in this area.
    Nutrition Research Reviews 07/2009; 22(1):49-67. DOI:10.1017/S0954422409990023 · 3.91 Impact Factor
Show more